Category: General

Therapix Biosciences Announces Expansion into Precision Medicine Through New Fully-Owned Subsidiary and Provides Corporate Update Today at the Biotech Showcase™ 2018

SHARE THIS POST Dr. Ascher Shmulewitz, Interim CEO, Discusses Strategy That Includes Additions to Drug Development TEL AVIV, Israel, Jan. 9, 2018 /PRNewswire/ — Therapix Biosciences Ltd. (NASDAQ: TRPX) (“Therapix” or the “Company”), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, is expanding into precision medicine through a new fully-owned subsidiary in order to develop novel solutions for pain. This new subsidiary will complement the Company’s cannabinoid-based drug development strategy. Ascher Shmulewitz, M.D., Ph.D., Interim CEO of Therapix, said, “We believe there is a large gap in medicine between current pharmaceutical treatments and the specific requirements of patients, which we plan to address. Recently, this gap has come into particular focus through the large and growing opioid crisis, which is having an extreme cost on human lives. The need for novel solutions has driven our decision to build a precision medicine arm while continuing to pursue our existing R&D efforts targeting the endocannabinoid system.” Therapix will elaborate on this additional strategic area of focus, with the goal of creating a full-circle, patient-centric approach during a corporate presentation today at 3:00 pm (PST) the Biotech Showcase™ 2018 in San Francisco, California. Therapix has previously announced a Memorandum of Understanding with Israel’s Assuta Medical Centers, Ltd., to develop first-in-class therapeutic products in the fields of precision medicine and cannabinoids. The Company has also announced a pre-clinical study...

Read More

MYM Acquires Budly, the “Uber of Cannabis”

SHARE THIS POST Vancouver, B.C., January 5, 2018 – MYM Nutraceuticals Inc. (CSE: MYM) (the “Company” or “MYM”) is pleased to announce that the Company has entered into a binding letter of intent with Budly Software Inc. (“Budly”), a leading software company that has developed a smartphone-enabled sales and distribution system connecting medicinal cannabis patients with local dispensary drivers for fast delivery and monitoring of orders.  Using the system, a customer can select a dispensary, place an order, and then choose a driver to deliver it.  The customer can then track the order on his smartphone and knows exactly when it will arrive.  Orders can be placed via the Budly app on iOS, Android and Windows phones, and via the website www.budly.com. “The Budly software is a game-changer for MYM because it brings us one step closer to becoming a fully integrated global cannabis company,” commented Rob Gietl, CEO of MYM. “Budly’s clean and simple interface allows orders to be easily placed by patients, right on their phone, and provides extensive back end management and logistics control for licensed producers and dispensaries.” The Budly system consists of two iOS apps, two Android apps, one web app, a dispensary backend admin and a master admin system.  The system also has advanced features such as GPS tracking of drivers, flexible geo-fencing adjustments for customers, and real-time order confirmations.  MYM intends to...

Read More

Neutrisci Announces A Major R&D MOU With Scientus Pharma To Develop A Medical Cannabinoid Retail Product

SHARE THIS POST Vancouver, British Columbia – January 8, 2018 – NeutriSci International Inc. (the “Company” or “NeutriSci”) (TSX-V: NU) (OTCQB: NRXCF) (FRANKFURT: 1N9), the innovator and pioneer behind neuenergy®, is pleased to announce it has entered into a major R&D Memorandum of Understanding with Scientus Pharma Inc. (“Scientus Pharma”). Under the terms of the MOU, both companies have agreed to share their technologies to develop, test, produce, and distribute a medical cannabinoid product for existing retail distribution networks across Canada. The core ingredients in NeutriSci’s products have significant anti-oxidant properties and health benefits. Scientus Pharma will conduct research on Neutrisci’s products and their components in combination with various cannabinoids. Research activities will initially be funded by Neutrisci. Both companies will have rights for further product development and testing, including potentially preclinical and clinical trials, which may be co-funded. NeutriSci President Mr. Glen Rehman stated, “This Scientus Pharma partnership helps position us at the forefront of developing new and innovative cannabinoid based medical products in Canada. Scientus Pharma, along with its existing partnerships, is sure to be a dominant player in the cannabis space in Canada. Through a collaborative effort, we will incorporate NeutriSci’s IP, technology and ingredients with Scientus’ expertise, proprietary technical know-how, and resources. By leveraging both parties existing partnerships, we will be positioned to offer the national retail consumer a safe, effective, dose controlled product that...

Read More

2017 Wrap-Up by Lexaria’s CEO

SHARE THIS POST Kelowna, British Columbia – January 8, 2018 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”) announces it’s been quite an amazing year for Lexaria stakeholders – the busiest and most productive we’ve had. I’ve welcomed so many new shareholders and Lexaria fans in 2017 and I want to ensure both our new followers as well as our long-term supporters remember just how much we’ve achieved in the past year. Financial Improvement In mid-2016 our finances were in rough shape and our balance sheet was weak. I made a promise to everyone back then that Lexaria’s first priority was to ensure we could survive as a strong and independent company. In October 2016 our first patent was granted by the US Patent and Trademark Office (USPTO) and that event – which we had been working on internally, quietly, for two years – changed everything. We’ve raised well over US$4 million in equity since then and paid off all our debt. We never stooped to sign any toxic convertible finance deals; not for a single minute did we forget that our first priority is to our shareholders and our moral and fiduciary duties are to act in the best interest of shareholders. Thus when we completed a brokered private placement early in the Spring of 2017 we did so at prices much closer to...

Read More

Isodiol International Inc. Signs Licensing Agreement With Level Brands Inc And Its Chairman Emeritus And Chief Brand Strategist Kathy Ireland

SHARE THIS POST Isodiol to begin marketing new line of phytoceutical products for kathy ireland® Health & Wellness and Ireland Men One January 8, 2018 – Vancouver, BC – Isodiol International Inc., (CSE: ISOL) (OTC:ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”), a global bioactive phytoceutical innovator specializing in the development of pharmaceutical and wellness products, announced today that it has entered into a licensing agreement with Level Brands Inc. (NYSE: LEVB), an innovative marketing and licensing company that provides bold, unconventional and socially responsible branding for leading businesses. Under the agreement, Isodiol will work with Level Brands to develop consumer products for its subsidiaries, kathy ireland® Health & Wellness and Ireland Men One (I’M1), the company’s lifestyle brand for men.  Encore Endeavor One (EE1), Level Brands’ corporate brand management and producer of experiential entertainment events, will provide strategic advisory services for the new wellness product lines. “We look forward to incorporating Kathy Ireland’s proven genius into Isodiol’s existing product strategy,” says Marcos Agramont, CEO of Isodiol.  “With more than 17,000 diverse offerings in the product line, Kathy Ireland has earned the confidence of millions and we are excited to introduce those consumers to the Isodiol brand.  She will bring tremendous energy into this burgeoning field and we look forward to working with her and the Level Brands’ team to provide safe, consistent, and highly bioactive cannabinoid products to the ever-expanding market.” kathy...

Read More

MPX Enters Into Management And Option Agreements with Production Facility And Second Dispensary In Maryland

SHARE THIS POST TORONTO, ONTARIO, January 8, 2018 – MPX Bioceutical Corporation (the “Company” or “MPX”) (CSE: MPX, OTC:MPXEF) today announced that the Company, through its indirect wholly-owned subsidiary, S8 Management, LLC (“S8 Management”), is entering into management agreements with each of Rosebud Organics, Inc. (“Rosebud”), which is authorized to purchase, process and sell medical cannabis products in Maryland, and Budding Rose, Inc. (“Budding Rose”), which is authorized to operate a dispensary and sell medical cannabis products in Maryland. Pursuant to the management agreements, S8 Management will provide all management services typically required by a production facility, in the case of Rosebud, and a dispensary facility, in the case of Budding Rose. Management services include, but are not limited to, all staffing, materials, equipment, logistical support, accounting and other administrative functions, contractor selection, advisory services and any other requirements essential to the successful operation of Rosebud and Budding Rose. In addition to managing the facilities, the Company, through its wholly-owned subsidiary, CGX Life Sciences, Inc. (“CGX”), will concurrently acquire options to purchase 100% of the issued and outstanding common stock of Rosebud for aggregate consideration of US$3,018,181.82 and Budding Rose for aggregate consideration of US$2,481,818.18. The options are each exercisable for a period of two (2) years. The Rosebud exercise price will be comprised of a cash payment of US$2,200,000 with the remainder of the purchase price satisfied by the...

Read More